HLX35

DRUG2 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Locally Advanced or Metastatic Solid TumorsSolid Tumor, AdultSquamous-cell Non-small Cell Lung Cancer

Phase 1

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Shanghai Henlius BiotechLocally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer

Start: 2022-06-03End: 2024-12-30Target: 82Updated: 2023-08-08

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Shanghai Henlius BiotechSolid Tumor, Adult

Start: 2023-01-06End: 2025-04-22Target: 30Updated: 2022-07-05